Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Accumulated Expenses: 2017-2025

Historic Other Accumulated Expenses for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $182,000.

  • Puma Biotechnology's Other Accumulated Expenses rose 124.69% to $182,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $182,000, marking a year-over-year increase of 124.69%. This contributed to the annual value of $111,000 for FY2024, which is 78.36% down from last year.
  • Latest data reveals that Puma Biotechnology reported Other Accumulated Expenses of $182,000 as of Q3 2025, which was down 18.39% from $223,000 recorded in Q2 2025.
  • Puma Biotechnology's Other Accumulated Expenses' 5-year high stood at $733,000 during Q2 2021, with a 5-year trough of $81,000 in Q3 2024.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $294,000 (2025), whereas its average is $303,364.
  • In the last 5 years, Puma Biotechnology's Other Accumulated Expenses skyrocketed by 138.60% in 2023 and then tumbled by 78.36% in 2024.
  • Over the past 5 years, Puma Biotechnology's Other Accumulated Expenses (Quarterly) stood at $632,000 in 2021, then tumbled by 65.98% to $215,000 in 2022, then skyrocketed by 138.60% to $513,000 in 2023, then crashed by 78.36% to $111,000 in 2024, then skyrocketed by 124.69% to $182,000 in 2025.
  • Its Other Accumulated Expenses stands at $182,000 for Q3 2025, versus $223,000 for Q2 2025 and $294,000 for Q1 2025.